ERBB2 and neoplasm: Trastuzumab, a recombinant form of DNA humanized IgG monoclonal antibody, can selectively bind with P185 glycoprotein regulated by the HER2 gene on the cell surface, thereby blocking the downstream oncogenic signal pathways of tumor cells, inhibiting tumor cell proliferation and neovascularization (6, 7).